Compare MSEX & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSEX | IOVA |
|---|---|---|
| Founded | 1897 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 940.9M | 968.6M |
| IPO Year | N/A | N/A |
| Metric | MSEX | IOVA |
|---|---|---|
| Price | $53.20 | $2.27 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 12 |
| Target Price | ★ $59.25 | $10.36 |
| AVG Volume (30 Days) | 145.5K | ★ 9.8M |
| Earning Date | 10-31-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.71% | N/A |
| EPS Growth | ★ 3.71 | N/A |
| EPS | ★ 2.39 | N/A |
| Revenue | $194,822,000.00 | ★ $250,425,000.00 |
| Revenue This Year | $3.92 | $60.94 |
| Revenue Next Year | $8.51 | $60.85 |
| P/E Ratio | $22.24 | ★ N/A |
| Revenue Growth | 6.24 | ★ 175.62 |
| 52 Week Low | $44.17 | $1.64 |
| 52 Week High | $67.09 | $8.56 |
| Indicator | MSEX | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 55.99 | 49.91 |
| Support Level | $51.55 | $2.18 |
| Resistance Level | $53.77 | $2.32 |
| Average True Range (ATR) | 1.57 | 0.12 |
| MACD | 0.46 | -0.01 |
| Stochastic Oscillator | 87.22 | 42.86 |
Middlesex Water Co owns and operates regulated water utility and wastewater systems in the U.S. The firm operates in the eastern states of New Jersey, Delaware, and Pennsylvania. The company has two operating segments, Regulated and Non-Regulated. The regulated business includes collecting and distributing water to residential, commercial, industrial, and fire protection consumers. The non-regulated business includes contract services for the operation of private water and wastewater systems. The majority of the company's revenue is derived from the Regulated segment and from residential customers.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.